Corrigendum to “Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: An MSBase Registry Sub-Study” [Multiple Sclerosis and Related Disorders Vol 106

Butzkueven, HelmutTaylor, LisaSpelman, TimKalincik, TomasBoz, CavitOzakbas, SerkanFarr, Pamela2026-04-252026-04-252026-052211-0348https://hdl.handle.net/20.500.14365/8991https://doi.org/10.1016/j.msard.2026.107131eninfo:eu-repo/semantics/openAccessCorrigendum to “Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: An MSBase Registry Sub-Study” [Multiple Sclerosis and Related Disorders Vol 106Feb 2026Article Number 106885] (Multiple Sclerosis and Related Disorders (2026) 106, (S2211034825006236), (10.1016/j.Msard.2025.106885))Erratum10.1016/j.msard.2026.1071312-s2.0-105035174525